

NEVIS BRANDS INC.
(formerly Pascal Biosciences Inc.)

VANCOUVER, BRITISH COLUMBIA, June 21, 2023- Nevis Brands Inc. (“**Nevis**” or the “**Company**”) (OTC:PSCBF) (FSE: 6PB-FF).

On May 18, 2023, the Company issued a news release regarding de-listing from the TSX.V. That news release said that shareholders of the Company owning 56% of the issued shares of the Company (“**Shares**”) approved the re-organization of the Company, including de-listing from the TSX.V.

The Company wishes to clarify that approval was not sought from all shareholders. There was no meeting of shareholders. Instead, the 56% shareholder approval was obtained by a written consent resolution from only some shareholders.

On Behalf of the Board of Directors

John Kueber
CEO, director

Company Contact:

John Kueber
Email: kueber@gmail.com
Phone: 425-380-2151

Forward-Looking Statements

DISCLAIMER

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products

may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.